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ABSTRACT 
In women of fertile age, iron loss consequent to excessive menstrual discharge is by 
far the most frequent cause of iron-deficient anemia. However, the relationship 
between menstrual discharge and iron loss is poorly understood. In this  prospective 
study, total menstrual and iron losses were assayed in a large cohort of non-anemic 
women and women with excessive menstrual blood losses (menorrhagia) in order to 
provide data useful for intervention. One hundred and five Caucasian women aged 
20-45 years were recruited. Blood cell count and serum ferritin (SF) levels were 
determined in each case before menses. Menstrual Fluid Losses (MFL) were 
determined using a standardized pads’ weight method. Hematin concentration was 
assayed by a variant of the Alkaline Hematin Method from which iron concentration 
was calculated. Mean SF levels were 36.2 (range 8.6-100) ng/ml in healthy women 
and 6.4 (range 5-14) ng/ml in patients with menorrhagia. Median values of iron 
lost/cycle were 0.87 mg in healthy women and 5.2 mg in patients with menorrhagia 
(ranges: 0.102-2.569 and 1.634-8.665 mg, respectively, p<0.001). In women with 
menorrhagia, iron lost/cycle strongly correlated (0.789, p<0.001) with MFL. In 
conclusion, healthy women with normal menses lose, on average, 1 mg iron/cycle. 
Average iron losses in patients with menorrhagia are, at least in our cohort, on 
average, 5-6 times higher than normal. Most women with menorrhagia had totally 
depleted iron stores. Indirect, quantitative evaluation of iron lost with menses may be 
useful to assess the risk of developing iron-deficient anemia in individual patients.  
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Introduction 
Iron is a vital element of metabolism, with the most obvious and known role played in 
erythropoiesis, and important functions in other intracellular processes in all tissues of 
the body. The uptake of iron is finely regulated (1). For physiologic iron losses, no 
known mechanisms of maintaining iron homeostasis have been identified, and losses 
appear to be related mainly to cell exfoliation (2).  
 
In general, the causes of iron deficiency are: i. insufficient dietary iron intake; ii. 
reduced absorption of iron in the intestines; and iii. the most common, blood loss. Iron 
supplementation is not only needed in conditions of absolute deficiency, but evidence 
has shown an important role of iron in the trophism and function of the heart muscle 
in cardiac failure, even in the presence of normal or high iron stores (3). Thus, it is not 
surprising that one of the first complaints of iron deficiency is tachycardia.  
 
As mentioned above, the leading cause of iron deficiency is acute or chronic blood 
loss, and the population bearing the highest risk for developing iron depletion is 
women of fertile age(4-6). This type of iron deficiency is often insidious as women 
have great difficulty in assessing the amount of their menstrual losses (7-9), and they 
may lose abnormally high amounts of blood during each menstruation period without 
being aware that the loss is excessive. In addition, neither the duration of menses nor 
the number of pads used is indicative of the actual blood loss (7). In the clinic, there 
are two main reasons why it is difficult to discern between ‘normal’ and ‘abnormal’ 
menstrual blood loss: firstly, the definition of ‘normal’ loss is largely subjective (7); 
and secondly, there are no simple and easily reproducible methods to measure blood 
losses. This explains why most cases of iron-deficient anemia in women with long-
standing menorrhagia are diagnosed after long periods of iron-deficient erythropoiesis 
(10).  
 
Iron requirements in women of fertile age are currently considered to be 15-20 
mg/day (6). However, on average, only 10% of dietary iron is absorbed. Furthermore, 
there is substantial variation in the level of iron absorption due to a number of 
interfering factors, including the type of dietary iron (heminic, non-heminic) and 
elements in the diet either favoring (vitamin C) or impairing (phytates, tannins, 
polyphenols) iron absorption (11). 
 
Knowledge of actual iron loss in women with ‘normal’ and ‘abnormal’ menstrual 
blood loss is scanty (9), and the relationship between iron loss and total menstrual loss 
is poorly understood, especially in women with menorrhagia. We believe that a 
detailed understanding of this relationship is important in order to prevent the 
development of iron-deficient anemia in this very frequent clinical setting. Therefore, 
we have evaluated total and day-by-day menstrual and iron losses on a large cohort of 
women with clearly defined ‘normal’ menstrual losses compared to a cohort of 
women with menorrhagia of various origins. 
 
Methods 
Subjects 
A sample of 105 Caucasian women was prospectively enrolled: 84 had ‘normal’ 
menses and 21 had menorrhagia. The latter were referred to our clinic for an inherited 
or acquired bleeding disorder: 3 on oral anticoagulants for deep vein thrombosis, 3 
with severe autosomally inherited bleeding disorders, 10 with dysfunctional uterine 
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bleeding, and 5 with fibromyoma. All 105 women were born in Italy, were aged 20-45 
years, and were recruited between January 2007 and October 2011 in three hospitals 
(Universities of L’Aquila and Palermo Academic Hospitals, and Research Hospital of 
S. Giovanni Rotondo). None of the women was pregnant or breastfeeding, none was 
taking oral contraceptive therapy for at least 3 months before enrollment, and none 
had medicated or non-medicated intra-uterine devices. Women with menorrhagia 
were diagnosed based on an internationally accepted parameter, MBL (12). The 
women with menorrhagia were exempt of treatments (i.e. hormone therapies, 
antifibrinolytics or replacement for their clotting defects). All subjects enrolled were 
administered a detailed general health and gynecologic questionnaire proposed by the 
SIGO (Società Italiana di Ginecologia ed Ostetricia) (13). In addition, a specific 
questionnaire produced for the calculation of the bleeding score in individuals with a 
‘mild bleeding disorder’ (type I von Willebrand disease) (14) was administered in 
order to rule out a mild, unknown underlying bleeding disorder. Individuals were 
asked to provide information about their blood group and had their blood counts and 
serum ferritin (SF) assay measured 1 week to 1 day before the menstrual cycle under 
scrutiny.  Informed consent was obtained from each patient enrolled in the current 
study 
 
Measurement of blood loss (Menstrual Fluid Losses; MFL) 
Participating women were asked to use the same brand and type of sanitary protection 
wears for the whole of their period, and to collect them using ad hoc labeled plastic 
bags. All women were instructed to collect all sanitary wears carefully to ensure 
minimal loss of menstrual flow in the toilet. All of the women used pads, except one 
woman who used tampons (internal sanitary wear). Participating women were asked 
to vacuum seal the plastic bags containing used wears promptly or at most within 2 
hours, and to complete the required information (ID number, date and hour of 
collection) on the sticker identifying each bag. The hour of the first wear discharge 
and sealing was considered to be the start time of the menstrual cycle. One dry 
sanitary wear (blank) of the same brand (and package) was also vacuum-sealed.  
 
At the end of each menstrual cycle, collected bags were sent to the Coordinator 
Center (Internal Medicine and Hematology Department, “San Salvatore” Hospital, 
L’Aquila). Bags were weighted on a scale sensitive to 1 g, and weights were recorded 
after subtraction of the blank. Weights represented the Menstrual Fluid Losses (MFL). 
In a preliminary study, vacuum sealing was shown to maintain the weight and the 
chemical properties of the discharges effectively for up to 4 weeks (data not shown). 
 
Measurement of iron loss (Menstrual Iron Losses; MIL) 
Hematin extraction was conducted using a modification of the Alkaline Hematin 
Method (AHM) technique (12,15). Standard spectrophometric analysis (Optical 
Density [OD]) was used to determine the concentration of hematin in each wear 
sample, using a standard curve obtained by diluting porcine hematin (Sigma-Aldrich, 
S. Louis, MO, USA). The following formula was applied to calculate hematin 
concentration (µM): OD hematin /0.0374)+0.02. Menstrual Iron Losses (MIL, μg/dl) 
were then calculated according the following formula: MIL= hematin concentration 
(µM) × 55.85/10. For each vacuum-sealed wear, the following results were obtained: 
1. MFL in ml of fluid discharge (blood and secretions) measured by the weight and 
converted in ml by multiplying each figure by 1.025, a conversion factor intermediate 
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between the specific weight of blood and lymph; 2. MIL (iron losses) in μg. Iron 
losses per day were calculated by dividing total losses by 28 (6).  
 
Statistical analysis 
The data description was based on standard measures of the distribution, such as 
median and mean for the position parameter and range and standard deviation (SD) 
for the variability. The normality of the parameter distribution was evaluated through 
the Kolmogorov Smirnov test. To evaluate parameter linear relations, we also 
calculated Pearson test and performed regression analysis. To compare median values 
of different groups, we used the Kruskal-Wallis test when the normality was rejected. 
Correlation analysis between sets of data was performed. Where useful, the 
confidence interval (CI) of the test value and the p-value (p) were provided. Analyses 
were conducted using the medcalc software version 7.4.1.2 (http:www.medcalc.be). 
 
This study protocol (MEVA-1 and MEVA-3) was first approved by the institutional 
review board (IRB) of the Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) 
San Giovanni Rotondo, and subsequently by the IRBs of the University of L’Aquila 
and Palermo, and was registered on clinicaltrial.gov (NCT01276964). The study has 
been been performed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments. 
 
Results 
Baseline demographic and clinical data 
Table 1 shows the demographic and clinical data pertaining to the 84 women with 
‘normal’ menses and the 21 women with menorrhagia.  
 
Women with ‘normal’ menses (n=84): Participants’ median age was 28 years, and 
median body mass index (BMI) was 21 kg/m
2
. Median menstruation duration was 5 
days, median interval between cycles was 28 days , median age at menarche was 12.0 
years , median hemoglobin (Hb) level was 13.4 g/dl, and median SF level was 29 
ng/L (Table 1).  
 
Women with menorrhagia (n=21): All women with menorrhagia failed to meet the 
requirements needed to define normally menstruating women.  Menstrual blood losses 
(MBL), preliminarily calculated with the AHM (7, 12), were >80 ml in every case 
(data not shown). The median age of women with menorrhagia was 33.5 years. BMI 
was not available. Median menstruation duration was 6 days and the median interval 
between cycles was 28 days. Median age at menarche was 12.0 years. Median Hb 
level was 10.9 g/dl and median SF level was 5.7 ng/L (Table 1).  
 
Menstrual and iron losses 
Table 2 compares data regarding MFL and MIL in both cohorts. Correlations between  
MIL and  blood Hb, SF and MFL, both in ‘normal’ women and women with 
menorrhagia are reported in Table 3. Furthermore, Table 3 reports correlation between 
SF and MFL both in ‘normal’ women and women with menorrhagia. Figure 1 
compares blood Hb and SF levels in normal women and women with menorrhagia. 
Figures 2 and 3 show total and day-by-day losses (MFL and MIL alike). 
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Discussion 
This study recruited a large number of women with either normal menses or 
menorrhagia to assess and compare menstrual and iron losses. Data showed that 
women with menorrhagia have a 5-6-fold higher loss of iron compared to women 
with normal menses, with a good correlation between the magnitude of blood loss 
(MFL) and iron loss (MIL) in both cohorts. In contrast, blood levels of Hb and SF do 
not predict losses.  
 
Study participants did not receive any treatment commonly recognized to be capable 
of modifying menses duration or intensity. Of note, no contraceptives of any kind 
were prescribed, nor were devices in place. This is important as anovulatory 
hormones (in the contraceptive pill) are known to reduce menstrual losses by half 
(16), and intrauterine devices may actually double menstrual losses (17). In women 
with menorrhagia, MBL exceeded 80 ml in every case (12), a figure that corresponds 
to 189 ml of MFL.  
 
We used two main approaches to evaluate menstrual discharge: a standardized pad 
weight assay method combined with a biochemical method that focused on the 
hematin concentration measurement after elution from the sanitary wears. The first 
approach (MFL) was indicative for blood and secretions discharged during the 
menses, and the second (MIL) was used to calculate directly the iron lost during the 
cycle.  
 
To the best of our knowledge, this is the first time that iron losses have been directly 
measured. A historic study (18) evaluated radio-iron (59Fe) kinetics in women with 
menorrhagia, and showed a sharply increased absorption and a rapid disappearance 
from the bloodstream. However, in this previous study, the evaluation of iron lost with 
menses was not performed. 
 
In the two cohorts in our study, day-by-day menstrual losses were notably different in 
terms of duration and daily distribution: in women with ‘normal’ menses, most of the 
blood losses were on days 1-3, whereas in women with menorrhagia, the peak blood 
loss was on day 2 (≈ 30%), with a gradual and slow decrease until day 7 (Figure 2,3).  
 
The comparative analysis between normally menstruating women and women with 
menorrhagia evidenced a clear-cut difference between the two cohorts, both in terms 
of total losses (MFL) and of iron losses (MIL). The difference is also evidenced in 
Figure 1 where blood Hb and SF levels were compared in the two cohorts. This can 
be ascribed to the strict method used to assess the range of ‘normality’. On average, 
women with menorrhagia had a 5-to-6-times higher iron loss per cycle (range 3-16) in 
comparison to women with normal menses, and very few women with menorrhagia 
overlapped the normal value distribution for MFL (n=2) and MIL (n=5).  
 
The present study showed that the correlation between MFL and MIL was very good, 
both in women with normal menses and in women with menorrhagia (Table 3 ), with 
about 65 ml of MFL accounting for 1 mg of iron lost (CI 930-1070 μg). In contrast, 
correlations between blood measurements (Hb and SF) and menstrual fluid 
measurements were fairly poor (Table 3), indicating that it is difficult to predict iron 
losses solely on the basis of blood parameters. However, a fairly good correlation was 
found between SF and MFL (in the cohort with menorrhagia only). Nevertheless, 
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these data show that the process to reach depleted iron stores is highly variable and 
may be of long duration, depending on both the baseline iron stores and the amount of 
iron lost per cycle. Other factors that may delay the identification of iron deficiency 
status include the choice of laboratory methods, the cut-off values used, the presence 
of other disorders, and the subjective recognition of related symptoms.  
 
Our data clearly showed that iron loss in women with menorrhagia was significantly 
higher than in the control group (Table 2). This is an expected finding, although its 
magnitude had not previously been reported. All of the women enrolled with 
menorrhagia had ferritin levels indicating that iron store depletion had already taken 
place; however, none of them, when referred to us, was taking iron therapy. Iron 
losses of the magnitude shown, and the fact that even women with normal 
menstruations have seldom replenished iron stores, suggests that the development of 
iron-deficient anemia is very likely in the short term. However, most of the time, 
women are referred to the gynecologist or the hematologist when iron depletion is 
well advanced. Instead, it would be important, from a clinical standpoint, to ascertain 
the abnormality of the menstrual losses as soon as possible when iron-deficient 
erythropoiesis has not yet developed. Based on these data, we suggest that treatment 
to correct iron-deficient erythropoiesis and replenish iron stores should be instituted 
as soon as possible, although the main obstacle is a late diagnosis of menorrhagia. 
Because of the poor predictive value of blood parameters concerning the amount of 
iron lost per menstrual cycle, even an indirect, quantitative evaluation of the iron lost 
with menses may provide elements useful to assess the risk of developing iron-
deficient anemia in individual patients. 
 
A possible limitation of this study is that we tested only one menstrual cycle. 
However, it is widely accepted that menstrual losses in individual women are fairly 
constant throughout their fertile age (19), a fact for which a genetic control has been 
proposed (20).  
 
In conclusion, this study demonstrates a correlation between the magnitude of 
menstrual blood loss (MFL) and iron loss (MIL), and a greater loss of iron in women 
with menorrhagia compared to women with normal menses. There is a lack of 
correlation between blood parameters (Hb and SF) with losses. These findings 
highlight the importance of early diagnosis of menorrhagia, assessment of iron loss, 
and prompt treatment to prevent iron-deficient anemia.  
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Figure legends 
 
Figure 1-Title: Serum ferritin and blood  Hemoglobin levels in women with 
normal menses and women with menorrhagia 
 
Legend: SF= Serum ferritin, Hb= Hemoglobin levels (Alberto effettivamente 
credo abbiamo invertito i nomi degli assi, no? E cioè in ordinata con i livelli 
da 7 a 16 dovremmo riferirci a Hb (g/dL), mentre in ascissa con i livelli da 0 a 
120 dobbiamo riportare la ferritina sierica SF in (ng/100ml)) 
 
 
Figure 2- Title= Mean Fluid Losses in normal and menorrhagic women 
 
Legend= MFL=Mean Fluid Losses, expressed as percentage of total during the 
different days of menses. Boxes indicate mean and whiskers Standard 
Deviation(?) 
 
 
 
Figure 2- Title= Mean Iron Losses in normal and menorrhagic women 
 
Legend= MIL=Mean Iron Losses, expressed as percentage of total during the 
different days of menses. Boxes indicate mean and whiskers Standard 
Deviation(?)  
 
 
